Literature DB >> 6379509

Intensive chemotherapy with autologous bone marrow rescue for recurrent malignant gliomas.

K Nomura, T Watanabe, O Nakamura, M Ohira, S Shibui, K Takakura, Y Miki.   

Abstract

Eight patients, four male and four female, were treated with high dose chemotherapy followed by bone marrow transplantation. In the first two patients, high dose ACNU was used for the treatment without combination with other drugs. This showed severe side effects such as intratumorous bleeding on the 18th day of treatment in the first case and pulmonary fibrosis on the 35th day of treatment in the second case. Considering these results, we considered another treatment schedule which consisted of high dose ADM (100 mg/m2), VCR (1.5 mg/m2), CDDP (80 mg/m2 X 4) and Ex (800 mg/m2) within seven days. Six patients were treated with this schedule and the results indicated that two patients had a partial response (more than 50% reduction of tumour size measured by CT scan), one had a complete remission (no tumour detected by CT scan), two showed no change and one, progression of the lesion. The patients recovered from the suppression of bone marrow function after the bone marrow transplantation as indicated. Granulocytes and platelets in blood began to increase from 10 to 14 days after the transplantation and became normal within three weeks after this. Serial measurements of S-GOT and alkaline phosphatase revealed reversible elevation, if any, within four weeks of the treatment. The number of our cases is still small, but results showed that autologous bone marrow transplantation made high dose chemotherapy possible. The necessity for consideration of the blood-brain barrier for this treatment is also discussed.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6379509     DOI: 10.1007/bf01743286

Source DB:  PubMed          Journal:  Neurosurg Rev        ISSN: 0344-5607            Impact factor:   3.042


  13 in total

1.  Experimental evaluation of potential anticancer agents VIII. Effects of certain nitrosoureas on intracerebral L1210 leukemia.

Authors:  F M SCHABEL; T P JOHNSTON; G S McCALEB; J A MONTGOMERY; W R LASTER; H E SKIPPER
Journal:  Cancer Res       Date:  1963-06       Impact factor: 12.701

2.  A phase III comparison of BCNU, hydroxyurea, and radiation therapy to BCNU and radiation therapy for treatment of primary malignant gliomas.

Authors:  V A Levin; C B Wilson; R Davis; W M Wara; T L Pischer; L Irwin
Journal:  J Neurosurg       Date:  1979-10       Impact factor: 5.115

3.  Technique for human marrow grafting.

Authors:  E D Thomas; R Storb
Journal:  Blood       Date:  1970-10       Impact factor: 22.113

4.  Studies on the chemotherapy of experimental brain tumors: evaluation of 1,3-bis(2-chloroethyl)-l-nitrosourea, cyclophosphamide, mithramycin, and methotrexate.

Authors:  W R Shapiro; J I Ausman; D P Rall
Journal:  Cancer Res       Date:  1970-09       Impact factor: 12.701

5.  Permeability characteristics of brain adjacent to tumors in rats.

Authors:  V A Levin; M Freeman-Dove; H D Landahl
Journal:  Arch Neurol       Date:  1975-12

6.  High-dose BCNU with autologous bone marrow rescue for recurrent glioblastoma multiforme.

Authors:  F H Hochberg; L M Parker; T Takvorian; G P Canellos; N T Zervas
Journal:  J Neurosurg       Date:  1981-04       Impact factor: 5.115

7.  Pulmonary toxicity associated with bischloroethylnitrosourea (BCNU).

Authors:  J R Durant; M J Norgard; T M Murad; A A Bartolucci; K H Langford
Journal:  Ann Intern Med       Date:  1979-02       Impact factor: 25.391

8.  High-dose BCNU therapy with autologous bone marrow infusion: preliminary observations.

Authors:  G Spitzer; K A Dicke; D S Verma; A Zander; K B McCredie
Journal:  Cancer Treat Rep       Date:  1979-08

9.  A toxicologic comparison of the potency and activity of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) in mice and rats.

Authors:  G R Thompson; R E Larson
Journal:  Toxicol Appl Pharmacol       Date:  1972-03       Impact factor: 4.219

10.  [High-dose chemotherapy with autologous bone marrow transplantation for malignant brain tumors].

Authors:  S Shibui; T Watanabe; Y Miki; K Nomura; M Ohira
Journal:  No Shinkei Geka       Date:  1983-07
View more
  5 in total

1.  Brain and plasma pharmacokinetics and anticancer activities of cyclophosphamide and phosphoramide mustard in the rat.

Authors:  S Genka; J Deutsch; P L Stahle; U H Shetty; V John; C Robinson; S I Rapoport; N H Greig
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

2.  Preliminary individual adjuvant therapy for gliomas based on the results of molecular biological analyses for drug-resistance genes.

Authors:  S Tanaka; H Kamitani; M R Amin; T Watanabe; H Oka; K Fujii; T Nagashima; T Hori
Journal:  J Neurooncol       Date:  2000       Impact factor: 4.130

Review 3.  High dose chemotherapy for the treatment of malignant brain tumors.

Authors:  S H Petersdorf; R B Livingston
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

4.  Preventive effects of interleukin 1 beta for ACNU-induced myelosuppression in malignant brain tumors: the experimental and preliminary clinical studies.

Authors:  S Tanaka; S Tabuchi; K Watanabe; H Takigawa; K Akatsuka; H Numata; Y Hokama; T Hori
Journal:  J Neurooncol       Date:  1992-10       Impact factor: 4.130

Review 5.  The expanding role of chemotherapy for pediatric supratentorial malignant gliomas.

Authors:  D C Lyden; W P Mason; J L Finlay
Journal:  J Neurooncol       Date:  1996 May-Jun       Impact factor: 4.130

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.